Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer.
Malou C P KuppenHans M WestgeestMaarten J van der DoelenAlphonsus Jm van den EertweghJules Llm CoenenKatja Kh AbenAlphons Cm van den BerghAndries M BergmanJoan van den BoschFiliz CelikMarieke H J van den Beuken-van EverdingenJules LavalayeSaskia van der MeerMarco B PoleeDiederik M SomfordInge M van OortCarin A Uyl-de GrootWinald R GerritsenPublished in: Future oncology (London, England) (2020)
Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line ≥3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line ≥3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.
Keyphrases
- rheumatoid arthritis
- prognostic factors
- disease activity
- end stage renal disease
- ankylosing spondylitis
- newly diagnosed
- chronic kidney disease
- ejection fraction
- interstitial lung disease
- small cell lung cancer
- systemic lupus erythematosus
- squamous cell carcinoma
- type diabetes
- systemic sclerosis
- skeletal muscle
- patient reported
- ultrasound guided